Ajanta Pharma Limited (NSE:AJANTPHARM)

Ajanta Pharma Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Operating Activities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Income	12,628	10,560	9,204	8,162	5,880	7,127
Depreciation & Amortization	1,756	1,678	1,388	1,304	1,267	1,214
Other Amortization	53.9	53.9	53.4	50.1	41	39.4
Loss (Gain) From Sale of Assets	16.3	18.7	6	-34.9	61.9	38.7
Loss (Gain) From Sale of Investments	-121.5	-80.4	-113.1	-20.1	14.8	-52.3
Stock-Based Compensation	88.6	15.3	38.8	54.9	2.2	3
Other Operating Activities	-639.2	-423.8	-793.7	-667.1	-14.1	-748.2
Change in Accounts Receivable	-4,141	-5,908	804.8	-1,789	-105.5	-2,697
Change in Inventory	-1,519	-309.5	-745.1	-123	-223.7	-256.6
Change in Accounts Payable	1,426	907.9	-84.5	408.5	969.1	-480.2
Change in Other Net Operating Assets	398.7	-1,219	1,814	505.5	28.6	1,430
Operating Cash Flow	9,948	5,292	11,572	7,851	7,921	5,617
Operating Cash Flow Growth	49.66%	-54.27%	47.41%	-0.89%	41.02%	-2.53%

Investing Activities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Capital Expenditures	-4,507	-3,652	-3,179	-1,524	-1,745	-1,488
Sale of Property, Plant & Equipment	-12.3	54.1	11.4	133.8	7.3	183.8
Investment in Securities	2,670	-1,142	-1,040	1,776	-3,907	287.8
Other Investing Activities	558.4	449.8	442.4	267.9	48.7	275.8
Investing Cash Flow	-1,291	-4,289	-3,765	653.9	-5,596	-741

Financing Activities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Long-Term Debt Issued	-	2,094	11	0.6	-	2.3
Total Debt Issued	102.7	2,094	11	0.6	-	2.3
Long-Term Debt Repaid	-	-114.9	-114.6	-125.5	-112.3	-137.5
Lease Payments	-45.2	-114.9	-114.6	-125.5	-107.4	-137.5
Net Debt Issued (Repaid)	-1,019	1,979	-103.6	-124.9	-112.3	-135.2
Issuance of Common Stock	-	-	0.1	-	-	-
Repurchase of Common Stock	-	-	-3,513	-3,883	-	-2,856
Common Dividends Paid	-7,493	-3,497	-3,494	-6,422	-896.9	-822.1
Other Financing Activities	-128.8	-161.1	-223.5	-81.3	-72.8	-783.9
Financing Cash Flow	-8,641	-1,679	-7,334	-10,511	-1,082	-4,597

Net Cash Flow

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Cash Flow	15.3	-676.5	473	-2,006	1,243	279

Free Cash Flow

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Free Cash Flow	5,441	1,640	8,393	6,327	6,176	4,129
Free Cash Flow Growth	68.41%	-80.46%	32.66%	2.44%	49.59%	2.02%
Free Cash Flow Margin	8.75%	3.01%	18.06%	15.03%	16.50%	12.36%
Free Cash Flow Per Share	43.52	13.13	67.05	50.21	48.20	31.84
Levered Free Cash Flow	2,986	-51.94	6,620	1,165	8,146	1,893
Unlevered Free Cash Flow	3,066	48.75	6,750	1,210	8,183	1,956
Free Cash Flow After Leases	5,395	1,525	8,279	6,201	6,069	3,991

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash Interest Paid	128.8	161.1	207.4	72.1	58.4	102
Cash Income Tax Paid	4,087	3,590	3,230	3,121	1,513	2,391
Change in Working Capital	-3,834	-6,529	1,789	-997.8	668.5	-2,004

Data Source: S&P Global Market Intelligence Last updated: Oct 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 10, 2026

Data Sources Report a data error